Pioneering Advances in Care and Education (PACE)

You may be eligible if

• Male \>=18 years of age and newly diagnosed prostate cancer (PCa) (within 3-months).
• Documentation of a low-risk PCa diagnosis as evidenced by clinical features of the following criteria:
• * PSA test at diagnosis \<=15 ng/ml
• * Localized PCa (cT1/T2,N0,M0)
• * Biopsy Gleason grade 2-6 OR (or 3+4 AND \<=33% cores are positive for adenocarcinoma)
• \*\*\*A minimum of 10 diagnostic cores taken by a systematic directed approach. Sampling may be obtained by target transrectal ultrasound (TRUS) or MRI imaging.
• * No treatment yet
• * No previous radiation or simultaneous use of androgen deprivation
• * Prior use of 5-alpha reductase inhibitor is allowed if they have been stopped for 6 or more months and biopsy performed when patient was not taking the drug
• * English language proficient and ability to provide informed consent
• * Managing urologist considers them a candidate for active surveillance
• Written informed consent (and assent when applicable) obtained from subject and ability for subject to comply with the requirements of the study, including the ability to read and speak English.
• 1. have pursued any active therapy for prostate cancer will be excluded;
• 2. are unable to read/speak English; or
• 3. if their managing urologist does NOT deem them as a candidate for active surveillance.